

Footfalls & Heartbeats



Commercialising a proprietary process that allows textiles to perform sensory functions with applications in health, athletics and composites.

COMPANY OVERVIEW

Footfalls & Heartbeats has developed a proprietary process for manufacturing smart knitted fabric to measure, in real-time, compressive force and tensile force. Using yarn interactions within the textile structure to make the fabric itself the sensor, we avoid the need for wires or miniature electronics in the garment.

In the last 12 months we have secured a licensing agreement with medi, one of the world's largest players in medical compression, and 3 additional letters of intent for applications in medical equipment and transport.

TECHNOLOGY AND PRODUCT

FHL's textile can currently measure compressive force and tensile force. This allows FHL to pursue multiple applications including compression bandages (its first product application), and preventing pressure injuries on hospital beds and wheelchairs.

FHL is also developing optical textiles, with potential application in medical, athletic and military areas in a global market that is increasingly demanding inexpensive and convenient sensor technologies.

KEY IMMEDIATE MARKETS

Medical Compression – \$2.5 billion
 Hospital beds & Wheelchairs – \$5.3 & \$4.5 billion
 Diabetic Ulcer Diagnosis – \$2.3 billion



KEY ACHIEVEMENTS



- Secured a licensing agreement with medi, one of the world's largest medical compression bandaging companies.
- The deal includes upfront payment on signing, payment on the milestone of product completion and also a royalty on sales of the product.
- Secured a Letter of Intent from a global manufacturer of office and public transport seat coverings.
- Secured a Letter of Intent from an international designer, maker and marketer of medical beds and stretchers.
- Secured a Letter of Intent from a company that develops and manufactures wheelchair seating.

- Completed a £175,000 grant from the UK government to develop a sock that may allow the early detection of the onset of diabetic foot ulcers, including £80,000 directed to FHL. The Technology Strategy Board (UK government) has requested that FHL UK Limited, with its collaborator, the University of Nottingham, apply for a larger grant to take this project forward.
- Secured \$250,000 Callaghan Innovation grant for co-funded project to further develop a vital vest.
- The Company has built upon its IP portfolio with two patent (PCT) applications and has filed a further provisional patent.
- Secured in-licensing deals and memorandum of understanding for future technology with Hong Kong PolyU, University of Nottingham and National Physics Laboratory (UK)

FINANCIALS				THE DEAL
	2015	2016	2017	
Revenue \$	840,000	1,660,000	3,750,000	FHL is seeking \$2million for 21% of the company with \$750,000+ already committed at \$39.50 per share on a \$7.49million valuation
Expenditure \$	1,420,000	1,795,000	1,731,000	
Profit (Loss) \$	-580,000	-135,000	2,019,000	